Biosearch Signs Agreement With C.R. Bard.

SOMERVILLE, N.J.--(BUSINESS WIRE)--March 1, 1999--Biosearch Medical Products Inc. (NASDAQ bulletin board: BMPI) announced that it reached an agreement on Feb. 25, 1999 with C.R. Bard Inc. (NYSE: BCR) headquartered in Murray Hill, N.J. to sell off its intermittent urinary catheter business, which includes custom made coating machinery.

The parties also reached an agreement, whereby Biosearch offered to manufacture and coat intermittent urinary catheter components for C.R. Bard Inc. until such time as it decides to perform these operations themselves.

Manfred F. Dyck, C.E.O. of Biosearch, indicated that these devices are sold in Europe due to differences in reimbursements. Without having an active marketing presence overseas, direct sales of these devices have been difficult. In the past few years, Biosearch sold catheter components to a large European company who finished, sterilized and packaged the intermittent catheter. When that relationship ended in 1998, another European presence was sought. C.R. Bard Inc. appeared to have such a presence which resulted in consummation of these transactions.

Proceeds of the sale have increased the working capital of Biosearch and allowed an increase of activities into its other product lines such as biliary stents, coagulation probes and biofeedback monitors.

Investors and other interested parties are urged to consult the 8K due to be filed shortly with the SEC (web site-www.sec.gov) which will explain in detail the financial aspects of the transaction. Biosearch also maintains a web site at www.biosearch.com.